Commonly, the aforementioned MRs all have known involvement with different parts of the MAPK/ERK signaling cascade, which is activated in over 40% of colon cancer cases, thus rationalizing the use of targeted anti-EGFR / VEGF therapies in combination with such HDACis [62, 64]. This evidence concerns the gene EGFR and malignant colon neoplasm.